// App-Quantinova.ai

245 : Remission/low disease activity is an achievable treatment target in psoriatic arthritis (PsA): results from a routine care European cohort of PsA patients treated with ustekinumab or TNF inhibitors

Researchers

Presenter

  • Stefan Siebert

Principal Investigators

  • Laure Gossec

  • Paul Bergmans

  • Kurt de Vlam

  • Elisa Gremese

  • Beatriz E Joven

  • Tatiana Korotaeva

  • Pamela B Wright

  • Toby Kent

  • Wim Noel

  • Michael Nurmohamed

  • Petros Sfikakis

  • Pavel Smirnov

  • Elke Theander

  • Josef Smolen

Medical Centers

  • Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK

  • Rheumatology, Pitié-Salpêtrière Hospital, APHP, Paris

  • Rheumatology, Sorbonne Université, Paris, FRANCE

  • Biometrics, Janssen-Cilag B.V., Breda, NETHERLANDS

  • Rheumatology, University Hospitals Leuven, Leuven, BELGIUM

  • Hematology Department, Fondazione Policlinico Universitario A. Gemelli, Universit Cattolica del Sacro Cuore, Rome, Italy

  • Rheumatology, Hospital Universitario 12 de Octubre, Madrid, SPAIN

  • VA Nasonova, Research Institute of Rheumatology, Moscow, RUSSIAN FEDERATION

  • Immunology, Janssen-Cilag Limited, High Wycombe, UNITED KINGDOM

  • Biometrics, Janssen-Cilag B.V., Beerse, BELGIUM

  • Rheumatology, VU University Medical Center, Amsterdam

  • Rheumatology Unit, st Dept of Propaedeutic Internal Medicine, Joint Academic Rheumatology Program, Athens University Medical School, Athens, Greece

  • Biometrics, Janssen-Cilag B.V., Moscow, RUSSIAN FEDERATION

  • Biometrics, Janssen-Cilag B.V., Solna, SWEDEN

  • Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria

Locations

  • United Kingdom

  • France

  • Netherlands

  • Belgium

  • Italy

  • Spain

  • Russia

  • Greece

  • Sweden

  • Austria

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • Malondialdehyde

  • Tumor necrosis factor

Drug/Treatment

  • Ustekinumab

Outcome

  • N/A

Study Design

  • Observational

  • Cohort

Phase

  • NA

Study Id's

  • NCT02627768

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved